
For most new medicines, developing for adults is only part of the obligation. The Paediatric Investigation Plan determines what a company must do for children[…]

Since the start of 2025, there is only one way to run a clinical trial in the EU. The Clinical Trials Regulation and its portal,[…]

The Clinical Trials Regulation (EU) No 536/2014 has reshaped how trials are authorised across Europe. Since the three-year transition period closed on 31 January 2025,[…]

Information security has quietly become a GMP concern. As pharmaceutical operations move to cloud platforms, connected instruments and AI-assisted systems, the confidentiality and integrity of[…]

The European Union’s medical technology rulebook — the Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR) — is the most demanding device[…]

The In Vitro Diagnostic Medical Devices Regulation (IVDR), Regulation (EU) 2017/746, has applied since 26 May 2022, replacing the long-standing In Vitro Diagnostic Directive (98/79/EC).[…]

For most new medicines in the EU, studying the product in children is not optional. Under the Paediatric Regulation, a paediatric investigation plan (PIP) must[…]

Advanced therapy medicinal products (ATMPs) — gene therapies, somatic-cell therapies and tissue-engineered products — are among the most complex products to bring to the European[…]

Orphan designation is one of the most valuable regulatory assets in Europe — and the rules that govern it are about to change for the[…]

The EU variations framework has just been through its most significant revision in over a decade — and the rules changed on a different date[…]